CRANFORD, N.J., Dec. 3, 2020 /PRNewswire/ -- Citius
Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a
specialty pharmaceutical company developing and commercializing
critical care drug products, today announced that it will be
participating in the Benzinga Global Small Cap Conference being
held virtually on December 8 and 9,
2020. Citius Chairman Leonard
Mazur will present at 11:30 am ET on Tuesday, December 8, 2020, and will host
one-on-one investor meetings.
Advanced investor registration for the conference and virtual
one-to-one meeting requests can be accessed here.
We are currently advancing four proprietary product
candidates: Mino-Lok®, CITI-002 (halobetasol-lidocaine
formulation or Halo-Lido), CITI-101
(Mino-Wrap), and CITI-401 (iMSC).
Mr. Mazur will discuss recent Company developments for these
product candidates including:
- Mino-Lok® is advancing in its Phase 3 trial
- A positive second interim analysis report from the independent
Drug Monitoring Committee (DMC) for the Mino-Lok pivotal Phase 3
trial
- The signing of an exclusive worldwide license agreement with
Novellus Therapeutics, Limited for a cellular therapy to treat
acute respiratory distress syndrome (ARDS), a leading complication
of COVID-19; and the formation of our Novecite, Inc.
subsidiary.
- Submission of a pre-investigational new drug (PIND)
consultation request for Mino-Wrap with written response and
guidance is expected
- Update on Halo-Lido which is anticipated to begin Phase
2b trial in the first quarter of
2021
About Citius Pharmaceuticals, Inc.
Citius is a late-stage specialty pharmaceutical company
dedicated to the development and commercialization of critical care
products, with a focus on anti-infectives and cancer care. For more
information, please visit www.citiuspharma.com.
Safe Harbor
This press release may contain "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Such statements
are made based on our expectations and beliefs concerning future
events impacting Citius. You can identify these statements by the
fact that they use words such as "will," "anticipate," "estimate,"
"expect," "should," and "may" and other words and terms of similar
meaning or use of future dates. Forward-looking statements are
based on management's current expectations and are subject to risks
and uncertainties that could negatively affect our business,
operating results, financial condition and stock price. Factors
that could cause actual results to differ materially from those
currently anticipated are: risks associated with conducting
clinical trials and drug development; our dependence on third-party
suppliers; our need for substantial additional funds; patent and
intellectual property matters; market and other conditions; our
ability to attract, integrate, and retain key personnel; the
estimated markets for our product candidates and the acceptance
thereof by any market; risks related to our growth strategy; risks
relating to the results of research and development activities;
uncertainties relating to preclinical and clinical testing; the
early stage of products under development; our ability to obtain,
perform under and maintain financing and strategic agreements and
relationships; our ability to identify, acquire, close and
integrate product candidates and companies successfully and on a
timely basis; government regulation; competition; as well as other
risks described in our SEC filings. We expressly disclaim any
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in our expectations or any changes in events,
conditions or circumstances on which any such statement is based,
except as required by law.
Contact:
Andrew Scott
Vice President, Corporate Development
(O) 908-967-6677 x105
(M) 646-522-8410
ascott@citiuspharma.com
View original
content:http://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-present-corporate-update-at-benzinga-global-small-cap-conference-on-december-8-301186114.html
SOURCE Citius Pharmaceuticals, Inc.